Resistance to Dolutegravir-A Chink in the Armor?
作者信息
Kuritzkes Daniel R
机构信息
Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
J Infect Dis. 2018 Jul 24;218(5):673-675. doi: 10.1093/infdis/jiy186.
Abstract
摘要
相似文献
1
Resistance to Dolutegravir-A Chink in the Armor?对多替拉韦的耐药性——盔甲上的一道裂缝？
J Infect Dis. 2018 Jul 24;218(5):673-675. doi: 10.1093/infdis/jiy186.
2
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.多替拉韦加拉米夫定联合治疗耐药的既往病例。
AIDS Res Hum Retroviruses. 2020 Apr;36(4):254-255. doi: 10.1089/AID.2019.0253. Epub 2020 Mar 9.
3
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.从多替拉韦加阿巴卡韦和拉米夫定转换为固定剂量比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺治疗病毒学抑制的 HIV-1 成人患者：一项随机、双盲、多中心、活性对照、3 期、非劣效性临床试验的 48 周结果。
Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18.
4
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.马拉维采用实用方法将多替拉韦作为一线治疗方案 1 年后的病毒抑制和 HIV-1 耐药情况：一项前瞻性队列研究。
Lancet HIV. 2022 Aug;9(8):e544-e553. doi: 10.1016/S2352-3018(22)00136-9.
5
Bictegravir and dolutegravir: head to head at 96 weeks.比克替拉韦与多替拉韦：96周疗效对比
Lancet HIV. 2019 Jun;6(6):e342-e343. doi: 10.1016/S2352-3018(19)30135-3. Epub 2019 May 5.
6
Mutations in the HIV-1 3'-Polypurine Tract Can Confer Dolutegravir Resistance.HIV-1 3'-多聚嘌呤序列中的突变可导致对多替拉韦产生耐药性。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0102721. doi: 10.1128/AAC.01027-21. Epub 2021 Oct 11.
7
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.二联治疗中多替拉韦的耐药障碍。
Antimicrob Agents Chemother. 2019 Feb 26;63(3). doi: 10.1128/AAC.02104-18. Print 2019 Mar.
8
Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.在HIV整合酶中，将E138K添加到R263K上可增加对多替拉韦的耐药性，但无法恢复HIV整合酶的活性和病毒复制能力。
J Antimicrob Chemother. 2014 Oct;69(10):2733-40. doi: 10.1093/jac/dku199. Epub 2014 Jun 10.
9
Is resistance to dolutegravir possible when this drug is used in first-line therapy?当多替拉韦用于一线治疗时，是否有可能出现对它的耐药性？
Viruses. 2014 Aug 27;6(9):3377-85. doi: 10.3390/v6093377.
10
[Resistance profile and genetic barrier of dolutegravir].[多替拉韦的耐药谱及基因屏障]
Enferm Infecc Microbiol Clin. 2015 Mar;33 Suppl 1:20-5. doi: 10.1016/S0213-005X(15)30005-7.
引用本文的文献
1
Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.基于多替拉韦的抗逆转录病毒疗法与其他联合抗逆转录病毒方案治疗 HIV 感染初治患者的比较：系统评价和荟萃分析。
PLoS One. 2019 Sep 10;14(9):e0222229. doi: 10.1371/journal.pone.0222229. eCollection 2019.
2
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.中低收入国家的三线抗逆转录病毒治疗（ACTG A5288）：一项前瞻性策略研究。
Lancet HIV. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29.
3
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.在使用卡替拉韦、比克替拉韦、多替拉韦和艾维雷韦的患者来源的临床分离株中出现的选择性耐药谱。
Retrovirology. 2018 Aug 17;15(1):56. doi: 10.1186/s12977-018-0440-3.
本文引用的文献
1
The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.S230R 整合酶取代与多替拉韦单药治疗期间病毒载量反弹相关，导致对整合酶链转移抑制剂的低水平耐药。
J Infect Dis. 2018 Jul 24;218(5):698-706. doi: 10.1093/infdis/jiy175.
2
HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.多替拉韦维持治疗失败的患者中 HIV-1 耐药性的动态变化。
J Infect Dis. 2018 Jul 24;218(5):688-697. doi: 10.1093/infdis/jiy176.
3
Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.多替拉韦利匹韦林治疗成人 HIV-1 病毒学抑制维持治疗的疗效、安全性和耐受性：III 期、随机、非劣效性 SWORD-1 和 SWORD-2 研究。
Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6.
4
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.ACTG A5353：多替拉韦加拉米夫定用于治疗 HIV-1 载量<500000 拷贝/mL 的初治 HIV-1 感染者的一项先导研究。
Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.
5
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.多替拉韦作为 HIV 的维持单药治疗（DOMONO）：一项 2 期、随机、非劣效性试验。
Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.
6
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.突变位于整合酶基因之外可赋予 HIV-1 整合酶链转移抑制剂耐药性。
mBio. 2017 Sep 26;8(5):e00922-17. doi: 10.1128/mBio.00922-17.
7
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.比克替拉韦、恩曲他滨与丙酚替诺福韦二吡呋酯复方片剂与多替拉韦加拉米夫定和丙酚替诺福韦二吡呋酯用于治疗人类免疫缺陷病毒 1 型感染的初始治疗（GS-US-380-1490）：一项随机、双盲、多中心、3 期、非劣效性试验。
Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31.
8
Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.比克替拉韦（GS-9883）的抗病毒活性，一种新型强效HIV-1整合酶链转移抑制剂，具有改善的耐药性谱。
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
9
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.《成人HIV感染治疗和预防用抗逆转录病毒药物：美国国际抗病毒学会专家组2016年建议》
JAMA. 2016 Jul 12;316(2):191-210. doi: 10.1001/jama.2016.8900.
10
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.三种不含非核苷类逆转录酶抑制剂的抗逆转录病毒方案用于初治HIV-1感染志愿者的疗效和耐受性：一项随机对照等效性试验。
Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084.
Zotero 插件